Duke is conducting limited clinical trials (5 cases with 100% success and no known side effects, although the "cure" is violent (because of the rapid rate of ca

Duke is conducting limited clinical trials (5 cases with 100% success and no known side effects, although the "cure" is violent (because of the rapid rate of cancer tissue destruction)) of an oncolytic virus, PVS-RIPO, an engineered poliovirus, on GBM. http://corporate.dukemedicine.org/news_and_publications/news_office/news/poliovirus-vaccine-trial-shows-early-promise-for-recurrent-glioblastoma http://corporate.dukemedicine.org/news_and_publications/news... The PVS-RIPO trial is available for recurrent glioblastoma patients with only one tumor. The tumor must be surgically accessible; the size must be no smaller than 1 cm and no larger than 5.5 cm, and the tumor must be located at least 1 cm away from the ventricles. Prior exposure to bevacizumab (Avastin) is permitted. For further information please contact the Preston Robert Tisch Brain Tumor Center at Duke at (919) 684-5301. http://www.cancer.duke.edu/btc/modules/Research3/index.php?id=41 http://www.cancer.duke.edu/btc/modules/Research3/index.php?i... Note: most clinical trials have other requirements such as age, gender, health condition, failed/doing/discontinuing other treatments, so it requires some persisence and research. See also: http://killingcancer.vice.com http://killingcancer.vice.com